Lost in translation: Dysregulation of cap-dependent translation and cancer

Cancer Cell

Volumn 5, Issue 6, 2004, Pages 519-523

  Bjornsti, Mary Ann ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INITIATION FACTOR 4E; INITIATION FACTOR 4G; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANGIOSARCOMA; APOPTOSIS; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LYMPHOMA; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRANSLATION INITIATION; TUMOR GROWTH;

MUS MUSCULUS;

EID: 2942518250     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.05.027     Document Type: Review

References (34)

1. Abid M.R., Li Y., Anthony C., De Benedetti A. Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication. J. Biol. Chem. 274:1999;35991-35998
2. Avdulov S., Li S., Michalek V., Berrichter D., Peterson M., Perlman D., Manivel J.C., Sonenberg N., Yee D., Bitterman P.B., Polunovsky V.A. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5:2004;. this issue
3. Bauer C., Brass N., Diesinger I., Kayser K., Grasser F.A., Meese E. Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int. J. Cancer. 98:2002;181-185
4. Bjornsti M.-A., Houghton P.J. The TOR pathway. A target for cancer therapy Nat. Cancer Rev. 4:2004;335-348
5. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4:2003;147-158
6. Carter P.S., Jarquin-Pardo M., De Benedetti A. Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E. evidence for internal ribosome repositioning in the human c-myc 5′UTR Oncogene. 18:1999;4326-4335
7. Chabes A., Georgieva B., Domkin V., Zhao X., Rothstein R., Thelander L. Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase. Cell. 112:2003;391-401
8. Cheadle J.P., Reeve M.P., Sampson J.R., Kwiatkowski D.J. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107:2000;97-114
9. De Benedetti A., Harris A.L. eIF4E expression in tumors. Its possible role in progression of malignancies Int. J. Biochem. Cell Biol. 31:1999;59-72
10. Dilling M.B., Germain G.S., Dudkin L., Jayaraman A.L., Zhang X., Harwood F.C., Houghton P.J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem. 277:2002;13907-13917
11. Gera J.F., Mellinghoff I.K., Shi Y., Rettig M.B., Tran C., Hsu J.H., Sawyers C.L., Lichtenstein A.K. AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 23:2003;23
12. Graff J.R., Boghaert E.R., De Benedetti A., Tudor D.L., Zimmer C.C., Chan S.K., Zimmer S.G. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int. J. Cancer. 60:1995;255-263
13. Gromov P.S., Madsen P., Tomerup N., Celis J.E. A novel approach for expression cloning of small GTPases. identification, tissue distribution and chromosome mapping of the human homolog of rheb FEBS Lett. 377:1995;221-226
14. Harris T.E., Lawrence J.C. Jr. TOR signaling. Sci. STKE Published online December. 9:2003;2003. 10.1126/stke.2122003re15
15. Hosoi H., Dilling M.B., Liu L.N., Danks M.K., Shikata T., Sekulic A., Abraham R.T., Lawrence J.C.J., Houghton P.J. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. 54:1998;815-824
16. Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., Germain G.S., Abraham R.T., Houghton P.J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59:1999;886-894
17. Huang S., Shu L., Dilling M.B., Easton J., Harwood F.C., Ichijo H., Houghton P.J. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol. Cell. 11:2003;1491-1501
18. Jiang H., Coleman J., Miskimins R., Miskimins W.K. Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int. 3:2003;2
19. Lazaris-Karatzas A., Sonenberg N. The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell. Biol. 12:1992;1234-1238
20. Lazaris-Karatzas A., Smith M.R., Frederickson R.M., Jaramillo M.L., Liu Y.L., Kung H.F., Sonenberg N. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev. 6:1992;1631-1642
21. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer. Rationale and promise Cancer Cell. 4:2003;257-262
22. Miyagi Y., Sugiyama A., Asai A., Okazaki T., Kuchino Y., Kerr S.J. Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell lines. Cancer Lett. 91:1995;247-252
23. Nomura M., He Z., Koyama I., Ma W.Y., Miyamoto K., Dong Z. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol. Carcinog. 38:2003;25-32
24. Rinker-Schaeffer C.W., Graff J.R., De Benedetti A., Zimmer S.G., Rhoads R.E. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer. 55:1993;841-847
25. Rosenwald I.B. Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells. Cancer Lett. 102:1996;113-123
26. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:2004;484-486
27. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell. 103:2000;253-262
28. Stocker H., Radimerski T., Schindelholz B., Wittwer F., Belawat P., Daram P., Breuer S., Thomas G., Hafen E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5:2003;559-565
29. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:2003;1259-1268
30. Topisirovic I., Culjkovic B., Cohen N., Perez J.M., Skrabanek L., Borden K.L. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO J. 22:2003;689-703
31. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501
32. Wendel H.-G., de Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:2004;332-337
33. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13:2003;2004-2008
34. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5:2003;578-581